Merck sues US government over Medicare drug price negotiation law.
Merck has filed a lawsuit against the US government over a law passed last year that allows Medicare to negotiate prices of certain medications. The pharmaceutical company claims that the provision is unconstitutional and threatens to stifle the industry's future investments in cancer treatments and other drugs. Medicare's new drug price negotiation program aims to lower prices for seniors, promote competition in the market, and strengthen Medicare. The law also imposes penalties on drug companies if they increase their prices faster than inflation, puts limits on Medicare out-of-pocket costs, and caps the price of insulin for Medicare beneficiaries at no more than $35 a month.
- Merck sues US government over new Medicare drug price negotiation program CNN
- Merck Sues Over Medicare Drug-Price Negotiation Law The New York Times
- Merck sues Biden administration over Medicare drug price negotiations CNBC
- Merck Sues US Over Inflation Reduction Act Barron's
- Merck Sues US Over Inflation Reduction Act Measures to Cut Drug Prices Bloomberg
Reading Insights
0
10
2 min
vs 3 min read
78%
474 → 105 words
Want the full story? Read the original article
Read on CNN